LONDON — September 6, 2026 at 12:24 p.m. BST. Spire Healthcare Group (LON:SPI) has agreed to a 250-pence cash takeover. Its shares last traded at 238 pence. That leaves a 5.0% gross return if the deal completes on those terms.
The 12-pence gap is not free money. Spire shareholders rejected another recommended 250-pence bid five years ago. This time, holders of 53.4% of the stock have pledged support, according to the Reuters report on Saturday’s agreement.
The weekend price gap
Cash terms versus the last undisturbed market close before the firm agreement.
The buyer is a consortium of funds managed by Toscafund, Three Hills and Ares. It values Spire’s share capital at about £1.026 billion, or $1.39 billion. The board described 250 pence as the highest proposal received during its strategic review.
“The acquisition represents the best available outcome for Spire shareholders,” chair-designate Debbie White said. Her case was not only about the premium. She cited a volatile sector and material wage and national-insurance pressures.
London was closed when the agreement landed. The last visible price therefore belongs to Friday. The London Stock Exchange recorded a 238-pence close, down 1.2%, on volume of 3.53 million shares.
The shares had not reached the bid
Daily closes for the final month before the recommended offer. Market data are current through .
Monday’s first price will be the market’s verdict on that risk. A quote near 250 pence would suggest high confidence in completion. A stubbornly wide discount would signal that investors want more certainty on votes, timetable or conditions.
The history deserves weight. Ramsay Health Care raised its recommended Spire offer to 250 pence in July 2021. Only 72.07% of shares voted at the court meeting backed the scheme, below the required 75%. The transaction lapsed.
Same price, different starting point
The 2021 result explains why a recommended deal can still trade below cash terms.
The comparison is useful, but not a replay. Spire’s earnings, ownership and financing backdrop have changed. A 250-pence payment in 2026 is also worth less in real terms than the same nominal figure in 2021.
The new offer carries a 66% premium to Spire’s market capitalisation on May 13, the day before the approach became public. That makes outright price resistance harder to infer. Yet the initial 53.4% backing is still below the 2021 vote that failed.
Spire brings real cash generation to the negotiation. Its 2025 results showed revenue rising 4.5% to £1.58 billion. Adjusted free cash flow climbed 64.9% to £64.3 million.
The buyer gets growth, cash and pressure
Full-year 2025 figures. Adjusted measures are Spire’s.
The weaker statutory profit shows what the headline premium does not. The operator remains exposed to wage inflation, hospital costs and shifts in NHS commissioning. Spire runs 38 hospitals and more than 55 clinics, so small margin changes travel across a large estate.
There is also a near-term information gap. Spire moved its half-year results from September 9 to a date no later than September 30. Investors may not see the fresh operating numbers before making early deal decisions.
Risks. A scheme vote, court approval and other closing conditions can still delay or defeat the transaction. A break would expose the shares to stand-alone trading. A competing bid could lift the payoff, but the board’s “highest proposal” language gives no evidence that one is coming.
The cleanest signal arrives when London reopens. The distance between Spire’s first Monday trade and 250 pence will price the market’s confidence. Until then, 5.0% is an opportunity with a warning label, not a forecast.
